Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

175.06 -8.66 (-4.71%)
Streaming Delayed Price Updated: 2:09 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

News headline image
What Analysts Are Saying About Axsome Therapeutics Stock ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
What Analysts Are Saying About Axsome Therapeutics Stock ↗
 
Via Benzinga
News headline image
Earnings Outlook For Axsome Therapeutics ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Axsome Therapeutics ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On Axsome Therapeutics ↗
 
Via Benzinga
News headline image
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 ↗
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
News headline image
3 Biotech Stocks to Buy and Hold for the Next 10 Years ↗
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
News headline image
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript ↗
AXSM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones ↗
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth. 
Via Benzinga
News headline image
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug ↗
The company is testing a treatment for patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
2 Stocks That Could Double Your Money in 5 Years ↗
These market-beating stocks could be just getting started. 
Via The Motley Fool
News headline image
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
News headline image
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
News headline image
Earnings Scheduled For February 20, 2024 ↗
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
News headline image
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK). 
Via Benzinga
News headline image
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says ↗
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates. 
Via Benzinga
News headline image
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years ↗
Is it too late to invest in these fast-growing stocks? 
Via The Motley Fool
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
The types of innovative drugs these companies develop are always in high demand. 
Via The Motley Fool
News headline image
Prediction: These 3 Stocks Will Soar in 2024 ↗
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
News headline image
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Unstoppable Stocks to Buy Right Now ↗
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
News headline image
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.